• EXO-OC clinical study preparations underway, with samples being procured to test for different ovarian cancer stages, high-risk groups and other diseases
• CAR-exosome in vivo proof-of-concept achieved, demonstrating superior tumour inhibition, excellent safety and precise tumour targeting in a TNBC mouse model
• A$10.2m capital raise completed to accelerate development of INOVIQ's ovarian cancer test and therapeutic programs

INOVIQ Ltd provided a quarterly business update, highlighting progress in its exosome diagnostic and therapeutic programs. In its exosome capture technology (EXO-NET®) business, the company reported growing customer numbers, particularly in the pharma/biotech and clinical segments. INOVIQ is also advancing discussions with diagnostic companies to develop custom NETs for isolating tissue-specific extracellular vesicles. For the EXO-OC™ ovarian cancer screening test, the company progressed sample acquisition for a larger clinical study to assess performance across different stages, high-risk groups and confounding diseases. INOVIQ remains focused on advancing EXO-OC to Laboratory Developed Test (LDT)-ready status by the end of 2026 and is in discussions with potential US laboratory partners for commercialisation. In the exosome therapeutics program, INOVIQ reported positive in vivo proof-of-concept results for its Epidermal Growth Factor Receptor (EGFR)-targeted CAR-Natural Killer (NK)-EVs in a triple-negative breast cancer (TNBC) mouse model. The study demonstrated excellent antitumour efficacy, a favourable safety profile, and precise tumour targeting. INOVIQ is accelerating its CAR-EV program into preclinical and manufacturing development, with additional data readouts expected in 2026. The company also provided an update on its neuCA15-3 breast cancer monitoring test, which is being advanced to a bead-based chemiluminescent assay. Financially, INOVIQ had A$13.8m in cash at the end of the quarter and completed a A$10.2m capital raise to accelerate the development of its exosome programs. The company also announced the appointment of Peter Gunzburg as Chairman and Dr Rebecca Lim as Chief Scientific Officer.

INOVIQ is strongly positioned for growth with a multi-product pipeline, strategic partners validating its patented technology, and an experienced leadership team. The company's priorities are to grow its EXO-NET® business, advance the EXO-OC™ ovarian cancer screening test toward commercialisation, accelerate development of its CAR-exosome therapy for breast cancer, and expand strategic partnerships to speed product development and commercialisation.